The Effect of UrsodeoXyCholicacid (UDCA) and ezetimibe on total faecal steRol ExcreTion and plasma lipid lEvels - EXCRETE

Academisch Medisch Centrum (AMC)0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•* Medical, surgical, laboratory or other conditions, which in the judgment of
•the Physician Investigator would make the subject unsuitable for enrollment, or
•potentially interfere with subject participation or completion of the study, *
•Suffering from an inflammatory bowel disease, e.g. Crohn*s disease or
•ulcerative colitis., * Suffering from gall stones or another biliary disease.,
•* Suffering diabetes mellitus (type I or II)., * Recent history of, or current
•drug or alcohol abuse, * AST or ALT levels > 2 x ULN, * Unable or unwilling to
•comply with the protocol requirements or deemed by the investigator to be unfit
•for the study., * Presence of contra indications for the use of UDCA and
•ezetimibe (see SPC), * Use of lipid lowering drugs such as the following:, o
•Statins and fibrates unless on a stable dose for at least 3 months prior to
•screening, o Use of nicotinic acid or derivates of nicotinic acid within 4
•weeks prior to screening, o Use of cholestyramine or colestipol, * Use of other
•drugs such as the following:, o Ciclosporine, o Antacids containing aluminium
•hydroxide or aluminium oxide, * Likely to leave the study before its completion

发起方

Academisch Medisch Centrum (AMC)